Short Interest in Ainos, Inc. (NASDAQ:AIMD) Declines By 41.9%

Ainos, Inc. (NASDAQ:AIMD) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totalling 52,200 shares, a decrease of 41.9% from the May 31st total of 89,900 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily volume of 623,800 shares, the short-interest ratio is currently 0.1 days.

Ainos Trading Down 3.9 %

AIMD stock opened at $0.81 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 0.32 and a quick ratio of 0.28. The firm has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $1.26. Ainos has a twelve month low of $0.77 and a twelve month high of $6.10.

Ainos (NASDAQ:AIMD) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.57) EPS for the quarter. Ainos had a negative return on equity of 55.38% and a negative net margin of 15,348.14%. The business had revenue of $0.02 million during the quarter.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.